◇ Daewoong Pharmaceutical to expand indications for new drugs in partnership with AI companies
Daewoong Pharmaceutical will strengthen new drug development capabilities by signing an agreement with an artificial intelligence (AI) company.
Daewoong Pharmaceutical (CEO Seungho Jeon) announced on the 22nd that it has signed a joint R&D agreement with Oncocross (CEO Lee Rang Kim), an artificial intelligence (AI)-based new drug development company at its headquarters in Samseong-dong.
Daewoong Pharmaceutical plans to expand the indications by incorporating Oncocross’s gene expression pattern-based AI platform’RAPTOR AI’ with the new drugs’Inabogliflozin’ and’DWN12088′ under development.
An anticancer drug in DWN12088, a PRS target treatment drug that expands the indication of Inabogliflozin, which is originally being developed as a treatment for diabetes, to metabolic diseases such as obesity, heart disease, kidney disease, etc., and uses refractory fibrosis appearing in the lungs, kidneys, and skin as an indication. And will explore new possibilities.
It is explained that the use of Oncocross’s AI platform can significantly shorten the new drug development process by discovering the optimal combination of treatments in a short time.
Oncocross is a company that possesses AI platform technology for finding new drug candidates and indications, and related big data. In recognition of its future value, Oncocross has invested a total of 25.5 billion won through series A and B respectively last year and last year in recognition of its future value. It has been childish. Daewoong Pharmaceutical also plans to make a certain strategic investment in Oncocross after signing the R&D agreement.
Daewoong Pharmaceutical CEO Seung-ho Jeon said, “With Oncocross’s bioinformatics-based excellent AI platform and Daewoong Pharmaceutical’s high ability to develop new drugs, the open collaboration has become a major trend in the pharmaceutical industry. We look forward to building a successful model of the drug,” he said. “Through this agreement, we will do our best to expand the new drug pipeline and contribute to improving the quality of life for patients.”
Meanwhile, Daewoong Pharmaceutical has been conducting joint research since last year to develop new anticancer drugs with A2A Pharma, an AI drug development company that specializes in identifying new target protein structures. Daewoong Pharmaceutical plans to maximize the productivity and value of the new drug pipeline by incorporating the data accumulated so far with the collaboration data with Oncocross.
◇ Yuhan Corp. invests 10 billion won in April Bio… listed as the 2nd largest shareholder
Yuhan Corporation (CEO, Wook-Je Cho) announced on the 23rd that it was listed as the second largest shareholder by investing 10 billion won in April Bio, which has Serum Albumin Fragment Associated (SAFA) technology, adding its existing stake.
Established in 2013, April Bio is a company specializing in new antibody drugs that develops global innovative new drugs in various therapeutic areas using its proprietary human antibody library (HuDVFab) technology and SAFA, a sustained platform technology that can increase the half-life of antibody fragmentation.
April Bio is preparing for phase 1 clinical trial in the United States this year, APB-A1, a preclinical inflammatory autoimmune disease drug (IL-18 target) APB-R3, male infertility treatment (FSH target) APB -R2, etc. are being developed.
Recently, April Bio decided to issue a paid-in capital increase of 10 billion won worth to a third party for Yuhan Corporation. In 2020, it attracted 18 billion won worth of Series B investment, and at this time Yuhan Corporation as a strategic investor (SI) invested 3 billion won in April Bio to acquire a 4.89% stake.
Since then, Yuhan Corporation and April Bio signed a’Joint Research New Drug Development Business Agreement’ to strengthen research cooperation, and the two companies are strengthening their partnership through additional investments.
In addition, the reason why Yuhan Corp., an existing strategic investor (SI), made additional investments is believed to be to further accelerate joint research using it in the future as the excellence of SAFA, an independent platform technology owned by April Bio, is recognized.
Meanwhile, April Bio is preparing for a special listing through technology evaluation on the KOSDAQ market this year.
Major financial investors are LB Investment, TS Investment, Hana Financial Investment, Ebest Investment & Securities, SJ Investment Partners, Daekyo Investment, Mirae Equity Partners, SM Cino Technology Investment, BSK Investment, Wooshin Venture Investment, and Kolon Investment.
◇Pharmaceutical Bio Association, held MR competency reinforcement training
For new employees in pharmaceutical sales with less than 3 years of experience…First come, first served
The Korea Pharmaceutical Bio Association (Chairman Hee-mok Won) announced on the 23rd that it is conducting the’MR Sales Competency Reinforcement Program’ for pharmaceutical sales managers (MRs).
The purpose of this training is to understand the role of MR and the basic competencies that must be possessed in accordance with the change in the business environment in the pharmaceutical bio field in the post-corona era, and to improve the sales strategy of a new approach. ‘This co-planned.
MR’s sales capabilities do not stop at simply delivering product information from the standpoint of manufacturers, but are required to identify unmet needs for effective treatment and various approaches for each customer.
Accordingly, this education provides a training program that can be used directly in the workplace based on systematic individual analysis of trainees.
Consisting of four parts, this training is organized as a 14-hour program, one part each month, and runs from April to July.
From Part 1 to Part 3, the analysis and systematization of MR capabilities, and relationship building strategies are the main points. Part 4 consists of an in-depth course that provides individual feedback after using it directly in the field based on the previously taught content.
The first training will be held on April 20 at 10 am in the auditorium on the 4th floor of the Association in Bangbae-dong, Seoul, under the theme of’The Role of MR and Communication Strategy & Business Analysis & Panning’.
The subject of training is a sales manager in the pharmaceutical bio industry with less than 3 years of experience, and it is a first-come-first-served basis with a capacity of 50 people.
Applications for training can be submitted through the application section of the notice on the Korea Pharmaceutical Bio Association website by the deadline.
◇Boo Chae-pyo Gasong Foundation-Korea Dental Association, selected as the 10th Yoon Kwang-Yeol Dental Medical Service Award Winner
Jointly awarded with’Asia Together’ with’Busan Gyeongnam Branch of the Dental Association for a Healthy Society’
The Gasong Foundation (Chairman, Dong Wha Pharm, Do-Joon Yoon) jointly selected the 10th Yoon Kwang-Yeol Dental Medical Service Award with the Korean Dental Association (Chairman Lee Sang-hoon) and selected’Asia Together’ with’Dentist Society Busan Gyeongnam Branch for a Healthy Society’ 23 Sun said.
The two organizations were honored with this award in recognition of their long-term dedication to improving the accessibility of dental care for marginalized neighbors. The awards ceremony is scheduled to be held on April 24 at the 70th General Assembly of the Korean Dental Association.
The Busan Gyeongnam Branch of the Dental Association for a Healthy Society was established in 1989 with the motto of’medical people who practice together for a healthy society’. Starting with the fluoridation of tap water in 1990, the company is promoting oral health related projects such as operating an oral health campaign and research and development of oral health policies. Since 2009, we have raised the Hope Fund to practice’Dentistry with Local Residents’, and have been conducting a child physician project in connection with 22 regional children’s centers.
In addition, the Busan Gyeongnam Branch of the Dental Association for a Healthy Society operates three free clinics for the disabled, migrant workers, and homeless people. Among them, the’Free Dental Clinic for Migrants in Jeonpo-dong’ is operated by volunteer activities by 21 dentists belonging to the group and about 30 students from Pusan National University School of Dentistry. For foreign migrants, 969 people from 14 countries were treated last year alone, and other clinics are conducting medical treatments for the vulnerable class of dental treatment, such as the residential vulnerable class, the homeless at the facility, and the dismissed worker.
‘Asia Together’, a co-winner, is a non-profit medical organization that provides free dental treatment for foreign workers and refugees residing in Korea, and was established to protect and practice the human rights of the socially underprivileged. In 2010, dental professionals gathered and started the first free treatment, and in 2017, 17 dental clinics participated in the opening of a dental clinic in Jongno-gu, Seoul, and they are continuing their medical volunteer work.
Asia, which has been treating 7600 patients for 11 years, is actively engaged in activities to resolve the medical blind spots of foreign workers and refugees and to protect the right to oral health.
In particular, clinics are striving to improve physical health and quality of life by activating conservative treatments and prosthetic treatments along with prophylactic treatments such as scaling to restore patients’ masticatory power.
Meanwhile, it has contributed to the spread of private medical service by forming networks with foreign worker organizations and multicultural business organizations nationwide, and by steadily providing free medical treatment using the human network of foreign parties.
The Yoon Gwang-yeol Dental Medical Service Award was jointly established by the Gasong Foundation and the Korean Dental Association in 2012, and marks the 10th anniversary of this year. It is awarded by selecting a person or organization dedicated to the promotion of oral health of the public.
The Gasong Foundation was established in April 2008 through the private appearances of Chairman Kwang-yeol Yoon and his wife, Kim Soon-nyeo, with the philosophy that’corporate profit must be returned to society’.
In addition to the Kwang-Yeol Yoon Dental Medical Service Award, Kwang-Yeol Yoon Medical Award (jointly established by the Korean Medical Association in 2009), Medical Contribution Award (jointly operated by the Korean Medical Association in 2017), Kwang-Yeol Yoon Pharmacy Award (co-established by the Korean Pharmacy Society in 2008), and Kwang-Yul Yoon Pharmaceutical Achievement Award (co-established by the Korean Pharmacy Society in 2019) ) To support academic research.
In addition, scholarships have been provided by selecting talented college students who have excellent academic achievements but are experiencing financial difficulties.
As part of the traditional culture support project, the’Summer Saengsaek Exhibition’, which started as an invitational exhibition with a fan as a motif, was expanded in 2011 to establish the Gasong Arts Awards in 2012, and it is also helping the development of culture and arts by discovering and sponsoring hidden talents in the art world.
◇Cheil Pharma Holdings-Cheil Pharm holds regular shareholders’ meeting
Cheil Pharma Holdings (CEO Sang-cheol Han) and Jeil Pharmaceutical (CEO Sung Seok-je) hold the 61st and 4th regular shareholders’ meetings in sequence at the headquarters auditorium starting at 9 am on the 23rd and pay 14% cash dividends each. decided.
On this day, Seong Suk-je, president of Cheil Pharmaceutical said, “The unprecedented new virus called’Corona 19′, which continues to this day, causes changes in daily life around the world and the resulting long-term economic downturn. Changes in the field are aggravated by difficulties that are difficult to handle, such as facing various challenges for the entire industry. “However, the unchanging support of shareholders sent last year and the dedication of all employees have resulted in a growth rate of 3% compared to the previous year. It was the driving force that enabled us to achieve this.”
Next, among the meaningful achievements made last year, global clinical preparation of’double target anticancer drug JPI-547′ and’reflux esophagitis treatment drug JP-1366′ by’Onconic Therapeutics’, a new drug development company established in May last year in the R&D field, and They pointed out that the major new drug’JPI-289 stroke treatment clinical phase 2A cohort3′ and the European clinical phase 1 of diabetes drug’JP-2266′ proceeded smoothly.
◇Cho-A Pharmaceutical launches’Benpotein Tablet’, a high-content active vitamin
On the 23rd, Cho-A Pharmaceutical (CEO Sung-Hwan Cho, Cho Sung-bae) announced on the 23rd that it has released’Benpotein Tablet’, a high-content active vitamin containing 300mg of benfotiamine (vitamin B1) and 100mg of pyridoxine (vitamin B6).
Benfotein tablets produce ATP, supply and synthesize nucleic acid constituent substances, synthesize benfotiamine and neurotransmitters necessary for the synthesis of neurotransmitters acetylcholine, serotonin and nerve myelin, metabolize proteins and carbohydrates necessary for ATP synthesis, synthesize hemoglobin, and absorb magnesium. It contains pyridoxine, which is necessary for the back.
Cho-A Pharm explained, “It is effective not only for muscle and nervous system diseases such as muscle pain, joint pain, and neuralgia, but also for lowering physical strength, improving physical fatigue, and enhancing immunity.”
Benfotein tablets are characterized by the highest content of benfotiamine among domestic products. Benfotiamine is an active vitamin B1 that combines an amphiphilic S-acyl group with a water-soluble thiamine, and has excellent absorption and bioavailability compared to general thiamine, and in particular, it is reported that its bioavailability is 4 times better than that of fursultiamine, which is the same active vitamin B1.
An official of Cho-A Pharmaceutical said, “It will be helpful for people suffering from physical fatigue, stomatitis, and inflammation in the mouth, patients with nervous system diseases such as joint pain and muscle pain, peripheral nerve abnormalities, etc., as well as physical strength recovery, immunity enhancement, and hangover relief.”
In addition, he said, “It is also recommended for Drug Mugger who has a lot of thiamin excretion due to alcohol intake and frequent medicine intake.”
Benpotein tablets can be easily taken once a day and one tablet once a day, and can be taken for a long time in 3 months. It can be purchased at a pharmacy, and inquiries about the product can be made through the customer service office of Cho-A Pharmaceutical.
◇Handok invests equity in Welt…Expand open innovation R&D as a digital treatment
Handok (CEO Kim Young-jin, Paik Jin-ki) and start-up Welt (CEO Kang Seong-ji) are working on the development of digital therapeutics.
On the 22nd, Handok made a stake investment of 3 billion won in Welt and signed a strategic partnership to jointly develop a digital treatment for alcoholism and insomnia.
Financial investors (FIs) in related fields also participated in this investment, and a total investment of 6 billion won was made.
This agreement is a part of the open innovation being unfolded by Korea and Germany. As a result, Handok expanded its R&D area to include new biopharmaceuticals and medical devices as well as digital therapeutics.
Handok plans to strengthen its capabilities in digital therapeutic research, development, and commercialization through Welt, and jointly develop a digital treatment for alcoholism and insomnia. In addition, it secures exclusive sales rights in the domestic market for these two treatments, and has the right to first review the domestic joint development and commercialization of digital treatments developed or planned by Welt.
Welt is a startup that spun off from Samsung Electronics in 2016. It cooperates with a number of government agencies, and is active as the first member of Asia in the’Digital Therapeutics Alliance (DTA)’, a global digital therapeutics industry association.
Welt is currently introducing the first digital therapy in Korea through partnerships with leading global digital therapy companies. This is related to a business agreement with the Ministry of Health and Welfare’s National Mental Health Center in 2020 for digital therapeutics for non-face-to-face mental health treatment.
Handok Chairman Kim Young-jin said, “I am very happy to cooperate with Welt, a leader in the field of digital therapeutics, amid the rapid growth of the digital healthcare market. “This will accelerate the development of innovative digital therapeutics.”
Seongji Kang, CEO of Welt, said, “For Welt’s first digital treatment in Korea to succeed, a partnership with Handok, which has various new drug development and business know-how, is essential.” We hope that welts will be able to exert synergy.”
Meanwhile, Handok is strengthening its R&D competitiveness through differentiated open innovation. Since 2006, when even the concept was unfamiliar in Korea,’Open Innovation’ has been selected as a future strategy, and research and development capabilities have been improved in a short time by linking with domestic and overseas research institutes and bio-ventures with excellent research capabilities.
It is collaborating with bio-ventures possessing excellent source technologies such as Genexine, SCM Life Science, and ABL Bio, and is strengthening global competitiveness by cooperating with US bio-venture Resolute. In addition, it is conducting joint research on innovative target anticancer drugs with CMG Pharmaceuticals and the National Anticancer Drug Development Project Group, and is developing medical devices with NB POSTECH and Handok Calos Medical.
Handok is establishing an R&D center in Magok to strengthen the competitiveness of open innovation, and it is planned to be completed by the end of this year.
◇Shinshin Pharm launches high content DHA Omega-3’Pycomega’ NS Home Shopping
Shinshin Pharmaceutical announced on the 23rd that it will officially launch a premium botanical Altage Omega-3’Pycomega’ with 98% DHA content through NS Home Shopping.
Pycomega is the first omega-3 health functional food launched by Shinshin HL, a health care brand that contains the philosophy and know-how of Shinshin Pharmaceutical.
Phycomega is a compound word of the prefix Phyco-, which means seaweed or algae, which is the source of sea life, and the essential fatty acid Omega-3, and is characterized by high DHA content using vegetable raw materials extracted from microalgae. to be.
Among the 200,000-300,000 species of microalgae in the world, the microalgae Schizochytrium, which has a particularly high DHA content, is cultivated with a patented technology, and the DHA ratio in the product reaches 98%.
DHA is a major component of brain and retinal tissues, and it helps blood circulation health by lowering the production of cholesterol and triglycerides in plasma. It is an essential component for our body to account for 97% of the fat component of the brain, but it is not sufficiently synthesized in the body and needs to be consumed separately.
In addition, Pycomega lowers the ratio of impurities and saturated fatty acids in the capsule and increases the purity, so even one capsule a day can sufficiently consume 600mg, which is more than the recommended intake of omega-3. In addition, it is a 100% vegetable product that does not use animal ingredients such as gelatin in capsules as well as raw materials.It is safe from marine pollution such as heavy metals, and does not smell fishy or fishy, so it can be consumed by consumers who are sensitive to odors and vegetarians without burden.
As it is a health functional food, care was taken to maximize the intake effect. It was extracted with the third-generation RTG-type molecular structure to increase the absorption rate and bioavailability in the body, and minimized the risk of fatal rancidity to omega-3 by 100% domestic process and individual packaging from microalgae cultivation to product production.
The launching broadcast of Shinshin HL Pycomega will be held through NS Home Shopping for 1 hour from 5:35 pm to 6:35 pm on the 23rd, and will be sold at a discount of up to 53% in commemoration of the launch. Customers who cannot purchase through home shopping can purchase them at various online shopping malls such as Gmarket, Auction, Coupang, 11th Street, Interpark, and WeMef, and will be sold at Naver Smart Store, the official online mall of Shinshin HL brand.
◇Bukwang Pharmaceutical, designated as an unfaithful disclosure corporation due to a simple error
On the 22nd of this month, Bukwang Pharm was designated as an unfaithful disclosure corporation due to the delay in disclosure and received two penalties.
Penalty points are given in consideration of the importance and motivation of the violation, and the two points are generally minor violations or negligence, and can be viewed as a situation due to simple error.
The delayed disclosure was due to the change in the minimum supply quantity due to the exclusion of Dexid Tablet, a new drug for improving diabetic neuropathy with Kalbe International, signed by Bukwang Pharmaceutical in 2014 due to the national licensing issue, resulting in a change in the contract amount from 16.8 billion won to 148. This is a part that has been reduced to billions of won.
Related contracts are automatically renewed every year, and in the process of extending the contract period due to this automatic renewal, it was delayed on March 2, 2021, recognizing that there was a change contract for the relevant matters in 2020.
Bukwang Pharm said, “This was caused by a simple error of the relevant department.” “After listing in 1988, except for this case, we have been working faithfully without disclosing unfaithfulness. We will do our best to conduct public announcements such as training.”
Copyright © Unauthorized reproduction and redistribution of medical news is prohibited.